250 related articles for article (PubMed ID: 37870697)
21. Evolving standards and future directions for systemic therapies in cervical cancer.
Ang DJM; Chan JJ
J Gynecol Oncol; 2024 Mar; 35(2):e65. PubMed ID: 38282261
[TBL] [Abstract][Full Text] [Related]
22. Advances in immunotherapy for cervical cancer: recent developments and future directions.
Sherer MV; Kotha NV; Williamson C; Mayadev J
Int J Gynecol Cancer; 2022 Mar; 32(3):281-287. PubMed ID: 35256414
[TBL] [Abstract][Full Text] [Related]
23. Advances in immunotherapy in cervical cancer.
Grau JF; Farinas-Madrid L; Garcia-Duran C; Garcia-Illescas D; Oaknin A
Int J Gynecol Cancer; 2023 Mar; 33(3):403-413. PubMed ID: 36878562
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy for metastatic and recurrent cervical cancer.
Scatchard K; Forrest JL; Flubacher M; Cornes P; Williams C
Cochrane Database Syst Rev; 2012 Oct; 10(10):CD006469. PubMed ID: 23076924
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy and Systemic Therapy in Metastatic/Recurrent Endometrial and Cervical Cancers.
Lima J; Ali Z; Banerjee S
Clin Oncol (R Coll Radiol); 2021 Sep; 33(9):608-615. PubMed ID: 34312021
[TBL] [Abstract][Full Text] [Related]
26. Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer.
Ge Y; Zhang Y; Zhao KN; Zhu H
Drug Des Devel Ther; 2022; 16():3055-3070. PubMed ID: 36110399
[TBL] [Abstract][Full Text] [Related]
27. The emerging treatment landscape of advanced urothelial carcinoma.
Cardenas L; Dibajnia P; Lalani AK
Curr Opin Support Palliat Care; 2021 Dec; 15(4):247-252. PubMed ID: 34620772
[TBL] [Abstract][Full Text] [Related]
28. Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.
Argiris A; Harrington KJ; Tahara M; Schulten J; Chomette P; Ferreira Castro A; Licitra L
Front Oncol; 2017; 7():72. PubMed ID: 28536670
[TBL] [Abstract][Full Text] [Related]
29. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.
McLachlan J; Boussios S; Okines A; Glaessgen D; Bodlar S; Kalaitzaki R; Taylor A; Lalondrelle S; Gore M; Kaye S; Banerjee S
Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):153-160. PubMed ID: 27838135
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy for recurrent and metastatic cervical cancer.
Tao X; Hu W; Ramirez PT; Kavanagh JJ
Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S67-71. PubMed ID: 18533239
[TBL] [Abstract][Full Text] [Related]
31. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Bednova O; Leyton JV
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
[TBL] [Abstract][Full Text] [Related]
32. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
Minion LE; Tewari KS
Gynecol Oncol; 2018 Mar; 148(3):609-621. PubMed ID: 29666026
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions.
Kagabu M; Nagasawa T; Sato C; Fukagawa Y; Kawamura H; Tomabechi H; Takemoto S; Shoji T; Baba T
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230938
[TBL] [Abstract][Full Text] [Related]
34. Recent breakthroughs in the management of locally advanced and recurrent/metastatic cervical cancer.
García E; Ayoub N; Tewari KS
J Gynecol Oncol; 2024 Jan; 35(1):e30. PubMed ID: 38072400
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
Turinetto M; Valsecchi AA; Tuninetti V; Scotto G; Borella F; Valabrega G
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408919
[TBL] [Abstract][Full Text] [Related]
36. Current status and novel insights into the role of metastasectomy in the era of immunotherapy.
Liatsou E; Tsilimigras DI; Malandrakis P; Gavriatopoulou M; Ntanasis-Stathopoulos I
Expert Rev Anticancer Ther; 2023 Jan; 23(1):57-66. PubMed ID: 36527305
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives.
Lim SM; Hong MH; Kim HR
Immune Netw; 2020 Feb; 20(1):e10. PubMed ID: 32158598
[TBL] [Abstract][Full Text] [Related]
38. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.
McNamara B; Chang Y; Mutlu L; Harold J; Santin AD
Expert Opin Biol Ther; 2023 Mar; 23(3):227-233. PubMed ID: 36800548
[TBL] [Abstract][Full Text] [Related]
39. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitors in cervical cancer: Current status and research progress.
Xie Y; Kong W; Zhao X; Zhang H; Luo D; Chen S
Front Oncol; 2022; 12():984896. PubMed ID: 36387196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]